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LETTER TO THE EDITOR
Impact of Randomized
Clinical Trials on
Clinical Practice
Regarding Treatment
of Lung Cancer
Few data are available on the im-
pact of clinical randomized trials on
clinical practice. Since 2000, several tri-
als regarding the effect of perioperative
chemotherapy (CT) on survival of non-
small cell lung cancer (NSCLC) have
been published or reported. Four adju-
vant CT trials1–4 were positive, and one5
failed to confirm a statistically signifi-
cant role for adjuvant CT. Further, one
trial was presented as positive at the
2004 ASCO meeting and became nega-
tive in 2006.6 For neoadjuvant CT, a
large trial7 showed an increase survival
of the preoperative CT arm with a sur-
vival difference of 8.6% at 4 years.
To assess the impact of those trials
on practice in France, two telephone
surveys were conducted: the first after
the results of the first trials in April 2004
and the second in December 2005 after
the results of the other studies. A sample
of 153 and 152 physicians, respectively,
involved in lung cancer treatment were
selected from an independent polling
organization. Questionnaires describing
clinical scenarios were telephoned to
those physicians. They were asked their
treatment option for two clinical cases
of resectable stage IB and IIB NSCLC.
Case 1 was a 50-year-old patient with a
resectable adenocarcinoma classified
T2N0M0 (IB). Case 2 was a 50-year-old
patient with resectable small-cell carci-
noma classified T2N1M0 (IIB). If peri-
operative CT was proposed, oncologists
were questioned about which CT regi-
men they would have prescribed to treat
this patient.
No statistical difference was ob-
served between the two samples of prac-
titioners questioned for the two surveys.
In 2004, one third of practitioners
would have treated a patient with stage
IB disease with perioperative CT before
(9%) or after (27%) surgery. In 2005,
suggested adjuvant CT increased from
27% to 58% (p  0.0001), whereas
neoadjuvant CT remained stable (p 
0.52). In 2004, most of the practitioners
treated stage IIB NSCLC with CT be-
fore (47%) or after (44%) surgery. In
2005, adjuvant CT increased from 44%
to 76% (p  0.0001), whereas propor-
tion of neoadjuvant CT remained stable
(p  0.64).
The two regimens of CT pre-
scribed were more often cisplatin-vi-
norelbine for adjuvant CT and cisplatin-
gemcitabine for neoadjuvant CT.
In a sample of 153 physicians (one
third of French oncologists), we found
evidence for rapid increase of prescrip-
tion of adjuvant CT, especially for pa-
tients with stage IIB disease. Similarly,
in Toronto, Ontario, Canada, the pre-
scription of adjuvant CT nearly doubled
(30% vs 56%) after the presentation of
positive trials at ASCO 2004.8
However, some limitations of our
surveys are possible: 1) we reported the
attitudes stated by practitioners on the
telephone, which may be different from
what would be observed in routine prac-
tice; and 2) factors other than physician
knowledge, including patient’s age, co-
morbidities, and preference, are involved
in a physician’s final decision. Addi-
tional studies, including medical chart
reviews, are still needed to evaluate the
impact of evidence-based medicine on
clinical practice.
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